glp-1 drugs covered by medicaid The evolving landscape of anti-obesity medication coverage in Pennsylvania Medicaid stopped covering GLP-1s

doi: 10.1210/jc.2014-2674% 63 SunMXQiaoFXXuZRLiuYCXuCLWangHLet al

Hong D, Si L, Jiang M et al (2019) Cost effectiveness of sodiumglucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases

doi: 10.1016/j.tcb.2015.11.004 231 KooJHGuanKL

Think of GLP-1 as your bodys built-in Im good, thanks signal

In the clinical trials, participants who managed to continue through week 12 had an 87% probability of achieving at least 15% total weight loss by week 48